Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469896 · ClinicalTrials.gov registry record · Phase 2
A Trial of Tocilizumab in ALS Subjects
A Phase 2 study, sponsored by Barrow Neurological Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02469896 is a Phase 2 study that has completed, run by Barrow Neurological Institute. The registered enrollment target is 22 participants.
The verdict
NCT02469896, a Phase 2 study, has completed, sponsored by Barrow Neurological Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects. Currently ALS has no cure and 2 modestly effective treatment to slow the progression of the disease. Although not the initial cause of ALS, the immune system plays a role in the death of motor neurons. The immune cells that participate in this process are stimulated by a substance called interleukin-6 (IL-6) whose effect is blocked by tocilizumab and thus, may slow the death of motor neurons and slow the disease.
Interventions
- OTHER Placebo
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469896
The ClinicalTrials.gov registry entry for NCT02469896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barrow Neurological Institute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02469896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469896 about?
NCT02469896 is a clinical study titled "A Trial of Tocilizumab in ALS Subjects". This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects. Currently ALS has no cure and 2 modestly effective t...
What is the current status of trial NCT02469896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-11. Estimated completion is 2018-07-11.
What interventions are being tested in trial NCT02469896?
The interventions under investigation include: Placebo (OTHER), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02469896?
This trial is sponsored by Barrow Neurological Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.